124 related articles for article (PubMed ID: 37202226)
1. FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell Lung Cancer.
Tan W; Zhang Y; Wang J; Zheng Z; Xing L; Sun X
Acad Radiol; 2023 Dec; 30(12):2904-2912. PubMed ID: 37202226
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
3. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
6. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
[TBL] [Abstract][Full Text] [Related]
8. Metabolic active tumour volume quantified on [
Rocha ALG; da Conceição MAM; da Cunha Sequeira Mano FXP; Martins HC; Costa GMLM; Dos Santos Oliveiros Paiva BCB; Lapa PAA
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3601-3611. PubMed ID: 34570257
[TBL] [Abstract][Full Text] [Related]
9. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
10. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
Finkle JH; Penney BC; Pu Y
Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
[TBL] [Abstract][Full Text] [Related]
11. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
12. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
Eude F; Guisier F; Salaün M; Thiberville L; Pressat-Laffouilhere T; Vera P; Decazes P
Ann Nucl Med; 2022 Mar; 36(3):224-234. PubMed ID: 35060071
[TBL] [Abstract][Full Text] [Related]
17. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
18. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
[TBL] [Abstract][Full Text] [Related]
20. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
Zhang H; Wroblewski K; Appelbaum D; Pu Y
Int J Comput Assist Radiol Surg; 2013 Mar; 8(2):181-91. PubMed ID: 22644386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
